FDA grants priority review for Genentech’s cervical cancer therapy

The US Food and Drug Administration (FDA) has accepted Roche subsidiary Genentech's supplemental biologics licence application (sBLA) and granted priority review for Avastin plus chemotherapy for treatment of women with persistent, recurrent or metas…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusions In the span of a very short time—less than a decade—robotic head and neck surgery has transformed the management of the head and neck cancer, and it seems clear that the future of treatment for these cancers lies in a multimodal approach in which TORS is likely to play an important role. Nevertheless, it is important to keep in mind that the current indications for TORS are limited and long-term data on the safety and oncological outcomes are needed to better understand the true role of TORS in treatment of head and neck cancer. Nonetheless, the emergence of ever more advanced robotic instruments i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study highlights how the use of in vitro 3D model can allow rapid screening and selection of new and safer drugs. Introduction Angiogenesis is a complex and finely regulated process that consists of the growth of new capillary blood vessels from pre-existing vessels to create communication pathways among tissues. The coordination of different activities such as endothelial cell proliferation and migration, metalloproteinase function, integrin expression and pericyte stabilization is essential for angiogenesis (Folkman, 1984). The “angiogenic switch” is “on” when the balance between pro-...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This study was supported by the Shanghai Sailing Program [grant number 17YF1425200, 2017]; Chinese National Natural Science Funding [grant number 81702249, 2017]; Science and Technology Commission of Shanghai Municipality [grant number 17511103403, 2017]; The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge the ex...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion In this article, we use the amphiphilic copolymer DSPE-SS-mPEG, which is connected by disulfide bonds. Afterward, the magnetic Fe3O4 nanoparticles and the hydrophobic drug are made by the self-assembly of the amphiphilic copolymer. DOX is encapsulated in the amphiphilic copolymer to form a magnetic nano drug controlled release system which is sensitive and responds to a reducing environment. This controlled release system can dissociate the disulfide bonds in the presence of dithiothreitol, thereby triggering the release system to disintegrate and expel the drug. When the DOX-loaded nanocarrier is transported ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We examined the following three conditions: DMEM high glucose which contained 4.5 mg/ml glucose, independent of serum, DMEM low glucose which contained 1.0 mg/ml glucose, independent of serum. And, DMEM no glucose which contained 0.0 mg/ml glucose, independent of serum. DMEM is referred to as glucose “free,” however some glucose was actually present due to the FBS. The glucose concentration in the FBS used was 1.04 mg/ml. We calculate 0.0937 mg/ml glucose was present in the media under all conditions due to the addition of serum. Quantification of ROS Levels ROS are widely evaluated in tissue culture using di...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, NC-LAP demonstrate antitumoral effect in HER-positive bladder cells by inducing cell cycle arrest and apoptosis exhibiting better effects compared to the non-encapsulated lapatinib. Our work suggests that the LAP loaded in nanoformulations could be a promising approach to treat tumors that presents EGFR overexpression phenotype. Introduction Bladder cancer (BC) is a heterogeneous disease which presents several molecular characteristics associated with different clinical outcomes (1). Urothelial or transitional cell carcinoma (TCC) represent the most frequent type of bladder cancer (2) and are classifie...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 February 2019Source: International Journal of PharmaceuticsAuthor(s): Cenk Daglioglu, Fatma Necmiye KaciAbstractChemotherapy frequently involves combination treatment protocols to maximize tumor cell killing. Unfortunately these intensive chemotherapeutic regimes, often show disappointing results due to the development of drug resistance and higher nonspecific toxicity on normal tissues. In cancer treatment, it is critically important to minimize toxicity while preserving efficacy. We have previously addressed this issue and proposed a nanoparticle-based combination therapy involving b...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conclusion: Current review has been highlighted on the novel medicinal agents from plant sources have potential effects against many types of cancer, which have been supported by clinical trials. The main findings of these active novel medicinal agents were also summarized and discussed here.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Cancer Therapy | Cervical Cancer | Chemotherapy | Food and Drug Administration (FDA) | Grants | Pharmaceuticals | Women